Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pepscan Therapeutics has entered into a research and licensing pact with Dutch developer of vaccines and antibodies, Crucell Holland.
Subscribe to our email newsletter
The tie up allows Crucell to use Pepscan’s proprietary technology to develop new vaccines targeting infectious diseases.
As per the terms of the agreement, Crucell is responsible to pay research funding and payments on achieving research and clinical milestones to Pepscan.
Additionally, Pepscan is also entitied to get royalties on sales of products resulting from the collaboration.
Pepscan CEO Wim Mol said they are convinced that Pepscan’s epitope mapping technology as well as their expertise in creating conformationally stabilized CLIPS peptides will greatly contribute to the development of novel vaccines.
"Together with our two recent R&D collaboration and licensing agreements with Tibotec Pharmaceuticals and Mercator Therapeutics, we consider this new agreement a further expression of our leadership position in lead finding and optimization of peptide drugs," Mol said.